Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Yanqi Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Prevention and Health Care Department of TCM, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Asthma, Network Pharmacology, Drugs, Chinese Herbal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Longhua Medical Scholar, "Shanghai Science and Technology Innovation Action Plan" Medical Innovation Research Special Project.
Abstract (Originalsprache)
KeChuanLiuWei‐Mixture (KCLW) is widely used as a Chinese medicine prescription to treat severe asthma. However, the underlying therapeutic mechanism of KCLW remains unclear. In this study, a network pharmacology method was used to identify the chemical constituents of KCLW by the TCMSP database and ultra‐performance liquid chromatography coupled with time‐of‐flight mass spectrometry. Differential expression identification, protein–protein interaction (PPI) network and functional enrichment analysis were used to screen key targets of KCLW for severe asthma. Our results confirmed that quercetin, luteolin, kaempferol, and wogonin are the most critical active ingredients in KCLW. Moreover, the 16 relevant severe asthma‐related targets of KCLW were obtained by overlapping the PPI networks of the KCLW putative targets and severe asthma‐related genes, among which the most important targets were IL‐6, NOS2, VEGFA, CXCL2, and PLAT. Functionally, the 16‐targets and their interacting differentially expressed genes were primarily related to biological functions and pathways related to immunity and inflammation, such as inflammatory response, T cell differentiation, Nrf2/HO‐1 signaling pathway, TGF‐β/Smad signaling pathway, and NF‐κB signaling pathway. KCLW inhibited inflammation in PDGF‐BB‐induced airway smooth muscle cells. In summary, this study demonstrates the active substance and potential therapeutic mechanism of KCLW in severe asthma, and offers a clinical direction for KCLW against severe asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prevention and Health Care Department of TCM, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Teaching and Practising Center, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Respiratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- Longhua Medical Scholar
- "Shanghai Science and Technology Innovation Action Plan" Medical Innovation Research Special Project
Zitieren
APA
Cheng, Y., Sun, D., Zou, L., Li, S., Tang, L., Yu, X., Tang, B., Wu, Y., & Fang, H. (2023). Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14302
Vancouver
Cheng Y, Sun D, Zou L, Li S, Tang L, Yu X, et al. Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14302
BibTeX
@article{Cheng2023,
author = {Cheng, Yanqi and Sun, Ding and Zou, Lu and Li, Shaobin and Tang, Ling and Yu, Xiao and Tang, Binqing and Wu, Yingen and Fang, Hong},
title = {Elucidation of the mechanisms and molecular targets of KeChuanLiuWei‐Mixture for treatment of severe asthma based on network pharmacology},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14302}
}
EUVIMED